SAM #PCA-NCI-09798

Sole Source Notice: GEM-X Cell QC, Sequencing, and Data Analysis Services for NCI

This notice announces the National Cancer Institute's intent to award a sole source contract to Psomagen, Inc. for specialized single cell sequencing and data analysis services. - Agency: National Cancer Institute (NCI), NIH, Department of Health and Human Services - Vendor: Psomagen, Inc. - Services required: - Quality control of single cell samples - Generation of sequencing libraries using 10X Chromium GEM-X Single Cell 5p RNA technology - Expression analysis data for frozen clinical xenograft biosamples - Proprietary requirement: Services must integrate with existing Psomagen data and processes - Sample viability constraint: Biosamples must be processed within 2 hours of transport - Sole source justification: Psomagen is the owner/developer of the required proprietary services - Commercial opportunity: Other vendors may submit capability statements if they can fully meet all requirements, including integration with Psomagen's data - No specific product line items; focus is on specialized laboratory services - No period of performance specified in the notice

Description

Title:  Psomagen, Inc. GEM-X Cell testing (ongoing studies)

This is a Notice of Intent to Sole Source (NOI), not a request for proposal. The National Cancer Institute intends to negotiate on an other-than-full-and-open competition basis with Psomagen, Inc., 1330 Piccard Dr., Suite 103, Rockville, MD  20850-4372 for quality control of submitted single cell samples, generation of sequencing libraries with 10X Chromium GEM-X Single Cell 5p RNA, and expression analysis data of (frozen) clinical xenograft biosamples.  The testing is being obtained from Psomagen, Inc.  to remain consistent with prior data of ongoing research studies.  A critical factor in filling the requirement is the limited viability (no more than 2 hours transport time) of the irreplaceable study biosamples. 

While this pre-solicitation does not constitute a solicitation, interested vendors may identify their interest and capability to satisfy this requirement. The Government understands that Psomagen, Inc. is the owner and developer of the required proprietary testing services currently used by NCI in its ongoing research studies.  However, vendors who believe that they can provide the capability required to fully meet the Government's requirement may submit a capabilities statement, including past performance, in writing to the identified point of contact prior to the closing date and time of this notice. Interested parties should clearly address the challenge of integrating with existing Psomagen quality control, sequencing libraries and expression analysis data.  Such documentation shall be evaluated solely for the purpose of determining whether or not to conduct this procurement on a competitive basis. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government. Interested parties may identify their interest and capability to respond to the requirement by referencing “PCA-NCI-09798.”

The statutory authority for this sole source requirement is 41 U.S.C. 3204(b)(2) as implemented by FAR Overhaul 12.102(a) only one source is available. THIS IS NOT A REQUEST FOR PROPOSAL.

All responsible sources that could provide comparable products may submit a capability statement via email to Christine Biser at:

ChristineBi@mail.nih.gov by 12:00 pm EASTERN Daylight Time, Wednesday, September 24, 2026.

Late submissions shall be treated in accordance with the solicitation provision at FAR 52.212-1(f). All responses received by the closing date of this synopsis will be considered by the Government. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.

Any questions or concerns regarding this solicitation should be forwarded in writing via e-mail to Christine Biser at ChristineBi@mail.nih.gov.

View original listing